By John Kerwin and Patrick Starremans, Resilience
The gene therapy and viral vector space have yet to achieve the level of standardization that typifies established modalities, such as monoclonal antibodies. Consequently, there exists a tremendous amount of diversity among these products. This demands a complex and bespoke CMC strategy, how can we overcome the need for an individualized approach for each product brought online?
